Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.

To systematically review all published economic analyses of the only 2 available agents for respiratory syncytial virus immunoprophylaxis in high-risk infants: respiratory syncytial virus immunoglobulin intravenous and palivizumab.